Drug: Xeloda
Generic: Capecitabin
Company: Roche ($RHHBY)
Patent expiration date: December 14, 2013
Estimated Global Sales 2012: $1.62 billion

The scoop: Xeloda has been around for more than a dozen years but continues to be a solid performer. The oral chemotherapy drug for breast and colorectal cancers saw sales grow 19% in 2011 on top of 13% growth in 2010. It is also in the enviable position of having no generic competition yet lined up against it. Roche settled a patent fight with Mylan ($MYL) last year. It granted the generics company a license, but the terms were undisclosed, so, it's not publicly known when Mylan will launch its version. And when it does, Roche's new experimental drug T-DM1 may be there to fill the vacuum. Studies of that drug show an improved overall survival rate and fewer side effects in breast cancer. The peak potential sales of it have been pegged at $5 billion.

For more:
Special Report: Xeloda - Top 10 Best-selling Cancer Drugs in 2011
Pfizer's Xalkori, Roche's TDM-1 among winners at ESMO
Cancer drugs lift Roche sales as charges slash earnings


Suggested Articles

Life sciences companies have pivoted quickly during COVID-19 - Syneos Health® is supporting more than 80 active COVID-19 projects, including vaccines.

New York's Covaxx has signed on with three South American nations to provide 140 million doses of its early-stage COVID-19 vaccine.

To get the COVID-19 vaccine out quickly, Pfizer has been running rehearsals at distribution sites, creating "growing confidence," U.S. officials said.